Trial Profile
A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Gilteritinib (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 20 Feb 2024 Planned End Date changed from 31 Dec 2024 to 31 Jul 2024.
- 04 Sep 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 20 Sep 2021 Planned End Date changed from 31 Mar 2022 to 31 Dec 2022.